CareDx Launches Two Expanded Indications for AlloSure Testing Services
AlloSure Heart is Now Validated and Commercially Available for Pediatric Heart Transplant Patients Under 15
AlloSure Kidney is Now Validated and Commercially Available for Simultaneous Pancreas-Kidney Transplant Patients
BRISBANE, Calif., March 11, 2025--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that AlloSure® is now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant.
Both indications are approved by the New York State Clinical Laboratory Evaluation Program, demonstrating that AlloSure has met the most rigorous validation standards for laboratory developed tests (LDTs).
AlloSure Heart, available for patients aged 15 years and older since 2020, is now clinically validated and commercially available for use in pediatric patients under 15, including infants. Studies have shown that AlloSure Heart can detect biopsy proven Acute Cellular Rejection (ACR) and AMR (Antibody Mediated Rejection) in all ages of pediatric heart transplant patients, consistent with its performance in adults.1-4 In a prospective study, the use of AlloSure dd-cfDNA for surveillance monitoring in pediatrics demonstrated an 81% reduction in surveillance endomyocardial biopsies (EMB).1
"The availability of AlloSure dd-cfDNA for all pediatric heart transplant patients is a major development. Our goal is for every one of our patients, including our youngest heart transplant recipients, to thrive with their transplanted heart. With molecular surveillance we can monitor organ health while avoiding the inconvenience and discomfort of unnecessary biopsies," said Dr. Brian Feingold, Medical Director, Pediatric Heart Transplantation, UPMC Children's Hospital of Pittsburgh. "We consider the use of surveillance biopsies outside of the first 2 or 3 months after transplantation to be outdated now that AlloSure is available for every pediatric heart transplant recipient."
Simultaneous pancreas-kidney (SPK) transplants are known to improve the quality of life and long-term survival of patients with insulin dependent diabetes and advanced renal disease.5 As with other organ transplants, the organs are at risk of rejection. AlloSure Kidney has been clinically validated to identify rejection and graft injury in SPK patients.6-7 AlloSure Kidney can improve the management of SPK patients by differentiating those at increased risk of rejection, who are otherwise stable, from patients at low likelihood of rejection.
"It is an honor to have led some of the early studies and to see that AlloSure Kidney is now clinically validated and commercially available for use in patients who have undergone simultaneous pancreas-kidney transplantation," said Dr. Dolamu Olaitan, MBBS, Transplant Surgeon, Rush University Medical Center. "I have witnessed firsthand the significant benefits for patients with diabetes and kidney failure of receiving a pancreas and kidney transplant. Now, we have a well-validated, non-invasive tool to monitor organ rejection and injury, which has the potential to improve their quality of life and long-term outcomes."
"We are thrilled to introduce two new expanded indications of AlloSure, addressing critical needs in transplant patient care. Until now, children under 15 who received a heart transplant could only be tested by exception, but now they can receive routine AlloSure Heart testing. Additionally, for patients who have undergone a simultaneous pancreas-kidney transplant, we have a solution to meet their needs," said Robert N. Woodward, CareDx Chief Scientific Officer.
In 2024, over 4,500 heart transplants were performed in the U.S. with about 10 percent under the age of 18.8 Additionally, in 2024 more than 700 patients received an SPK transplant.8
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit www.caredx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with AlloSure Heart and AlloSure Kidney. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond CareDx's control, that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloSure Heart and AlloSure Kidney. These statements are also subject to general economic and market factors, and global economic and marketplace uncertainties, among other risks discussed in CareDx's filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
References:
Feingold B, Rose-Felker K, West SC, et al. Early findings after integration of donor-derived cell-free DNA into clinical care following pediatric heart transplantation. Pediatr Transplant. 2022 Feb;26(1):e14124. doi: 10.1111/petr.14124.
O'Halloran CP, Tannous P, Arva NC, et al. Histopathology, mRNA expression profile, and donor-derived cell-free DNA for assessment of rejection in pediatric heart transplantation. Pediatr Transplant. 2024 May;28(3):e14705. doi: 10.1111/petr.14705.
Akabas L, Bravo SA, Zhang Y, et al. Progress in Noninvasive Surveillance for Acute Rejection in Pediatric Heart Transplant Recipients: A Real-World Analysis of Donor-Derived Cell-Free DNA-Based Surveillance Protocol. Clin Transplant. 2024 Oct;38(10):e15481. doi: 10.1111/ctr.15481.
Feingold B, Rose-Felker K, West SC, et al. Short-term clinical outcomes and predicted cost savings of dd-cfDNA-led surveillance after pediatric heart transplantation. Clin Transplant. 2023 May;37(5):e14933. doi: 10.1111/ctr.14933.
Boggi U, Vistoli F, Andres A, Arbogast, et al. First World Consensus Conference on pancreas transplantation: Part II - recommendations. Am J Transplant. 2021 Sep;21 Suppl 3(Suppl 3):17-59. doi: 10.1111/ajt.16750.
Yoo A, Riedel A, Qian I, et al. An Initial Analysis of the Baseline Levels of Dd-cfDNA After Pancreas Transplantation: A Prospective Study From High-volume Centers in the United States. Transplant Direct. 2023 Mar 15;9(4):e1459. doi: 10.1097/TXD.0000000000001459.
Williams MD, Fei M, Schadde E, et al. Early Experience Using Donor-derived Cell-free DNA for Surveillance of Rejection Following Simultaneous Pancreas and Kidney Transplantation. Transplant Direct. 2022 Apr 7;8(5):e1321. doi: 10.1097/TXD.0000000000001321.
OPTN HRSA national database https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/, Accessed online March 6, 2025.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311545939/en/
Contacts
CareDx Media ContactsAnna Czene818-731-2203aczene@caredx.com
Investor RelationsCaroline Cornerinvestor@caredx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Meet Riley, the newest ‘Home Runs for Life' honoree
Lego time is special for Jason and Tracy Olmstead, and their 9-year-old son, Riley. 'Legos are really good (occupational therapy) aren't they, (Riley)?' Jason Olmstead said. It's a moment the Olmstead family doesn't take for granted. In the summer of 2022, Riley was having headaches and had an MRI. 'I remember sitting in the emergency room and just not talking,' Tracy Olmstead said. In July 2022, Riley was diagnosed with medulloblastoma, a rare form of brain cancer.'You're trying to figure out why, and if you could have prevented it, but this isn't something you could have prevented,' Tracy Olmstead said.'(Medulloblastoma) can effect balance, strength, coordination,' said Emily Vickers, a MercyOne Genesis physical therapist. 'It can lead to changes in behavior, changes in speech difficulty.' From there, Riley started treatment at MercyOne Genesis' GOPEDS program. '(Riley was) able to sit up and be stable. We moved to getting (Riley) mobility, moving around the room either by crawling or scooting around,' Vickers said. 'He had very little endurance when he started. So we've worked on increasing that so that he can play for longer periods of time and actually participate in therapy. We had a lot of breaks early on.' Through it all, though, Riley has not complained. 'He knows that he is my hero,' Tracy Olmstead said. Waiting for Riley at Modern Woodmen Park is a hero's welcome. Riley is the newest 'Home Runs for Life' honoree. 'We want them to see that you can get through anything, and that he has gotten through anything. He is just a strong, amazing boy,' Jason Olmstead said. As Riley rounds the bases, it's a moment to remember the medical hurdles he's overcome. 'It's gonna be amazing. It's gonna get the word out about medulloblastoma,' Tracy Olmstead said. To learn more about MercyOne Genesis' GOPEDS program, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Little Rock Zoo's oldest elephant tests positive for tuberculosis
LITTLE ROCK, Ark. — The Little Rock Zoo's oldest elephant has tested positive for tuberculosis following a routine exam. The elephant's name is Zina and she was diagnosed after a trunk wash test showed that she was shedding the bacteria. According to zoo officials, Zina is receiving treatment to stop bacterial shedding and prevent transmission to other animals. Little Rock Zoo shares growth update on baby gorilla Beni Staff will continue frequent monitoring and blood work during Zina's treatment, as the medication can be hard on her system. Tuberculosis is a zoonotic disease but primarily affects humans and is commonly seen in older Asian elephants imported from Southeast Asia before the 1970, Zoo officials said. Little Rock Zoo celebrates 100 years with community-focused centennial event A spokesperson added that guests are not at risk due to the distance maintained between the animals and visitors. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
UPMC renames ICU to honor fallen Officer Andrew Duarte
YORK, Pa. (WHTM) – The UPMC Memorial Hospital in York dedicated its Intensive Care Unit to Fallen West York Officer Andrew Duarte, who died during a mass shooting at the hospital in February. 'When you step off the elevator, you see his picture and his date of birth and death date,' Duarte's mother, Nancy Duarte Matarese said. 'I just look at it and that's my sweet child.' Duarte's name is also above the ICU doors. 'He was an amazing young man,' Duarte's father, Gary Duarte said. 'From the day he was born, he did nothing but make us proud.' Officers came from across the country, including Colorado, where Duarte used to serve as an officer. Download the abc27 News+ app on your Roku, Amazon Fire TV Stick, and Apple TV devices 'He was a warrior, no doubt,' his former colleague, Lt. Alan Ma said. 'He was a true friend and a dear colleague.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
